Warning: bisphosphonates and osteochemonecrosis of the jaws.
The aim of this article is to highlight the link between bisphosphonates and osteonecrotic lesions of the jaws ("osteochemonecrosis") and to alert general practitioners to the implications these drugs may have on their day-to-day practice. We review the use of this class of drug, the indications for which have widened recently, describe their effect on bone metabolism and outline the proposed mechanism for bisphosphonate-induced osteochemonecrosis. Predisposing and initiating factors and management are outlined, and suggestions made as to how the dental profession can help with this increasingly prevalent problem.
Flint
Stephen R
SR
Dublin Dental School and Hospital, Trinity College Dublin.
Sharkey
Seamus
S
Galvin
Sheila
S
D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D016723:Bone Remodeling / Q000187:drug effects; D003729:Dental Care / Q000009:adverse effects / Q000379:methods; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced* / Q000175:diagnosis; D009369:Neoplasms / Q000188:drug therapy; D010010:Osteoclasts / Q000187:drug effects; D010020:Osteonecrosis / Q000139:chemically induced* / Q000175:diagnosis; D010024:Osteoporosis / Q000188:drug therapy; D012307:Risk Factors; D014945:Wound Healing / Q000502:physiology
D050071:Bone Density Conservation Agents; D004164:Diphosphonates